The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia

Musa Yilmaz; Samantha Richard; Elias Jabbour

doi:10.1177/2040620715596715

The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia

Musa Yilmaz, Samantha Richard, Elias Jabbour

Leukemia

Research output: Contribution to journal › Review article › peer-review

22 Scopus citations

Abstract

Antibody-drug conjugates (ADCs) are likely to make a significant contribution in the treatment of acute lymphoblastic leukemia (ALL) by combining the cytotoxicity of chemotherapy with the specificity of monoclonal antibodies. CD22, an endocytic receptor expressed by the majority of B cells, is an excellent target for ADCs. Inotuzumab ozogamicin (INO) is an ADC that consists of a cytotoxic moiety (derivative of calicheamicin) attached to a humanized monoclonal anti-CD22 antibody. As a single agent, INO, was shown to be effective with an objective response rate of 50% in the treatment of relapsed and refractory CD22 positive ALL patients. Clinical trials investigating the combination of INO with the conventional chemotherapies are ongoing. This review summarizes the clinical potential of INO in treatment of relapsed and refractory ALL, based on currently available data in the literature.

Original language	English (US)
Pages (from-to)	253-261
Number of pages	9
Journal	Therapeutic Advances in Hematology
Volume	6
Issue number	5
DOIs	https://doi.org/10.1177/2040620715596715
State	Published - Oct 2015

Keywords

acute lymphoblastic leukemia
inotuzumab ozogamicin
refractory
relapsed
salvage

ASJC Scopus subject areas

Hematology

Access to Document

10.1177/2040620715596715

Cite this

@article{92174f2073164c4ba94b9f72ec97a25e,

title = "The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia",

abstract = "Antibody-drug conjugates (ADCs) are likely to make a significant contribution in the treatment of acute lymphoblastic leukemia (ALL) by combining the cytotoxicity of chemotherapy with the specificity of monoclonal antibodies. CD22, an endocytic receptor expressed by the majority of B cells, is an excellent target for ADCs. Inotuzumab ozogamicin (INO) is an ADC that consists of a cytotoxic moiety (derivative of calicheamicin) attached to a humanized monoclonal anti-CD22 antibody. As a single agent, INO, was shown to be effective with an objective response rate of 50% in the treatment of relapsed and refractory CD22 positive ALL patients. Clinical trials investigating the combination of INO with the conventional chemotherapies are ongoing. This review summarizes the clinical potential of INO in treatment of relapsed and refractory ALL, based on currently available data in the literature.",

keywords = "acute lymphoblastic leukemia, inotuzumab ozogamicin, refractory, relapsed, salvage",

author = "Musa Yilmaz and Samantha Richard and Elias Jabbour",

year = "2015",

month = oct,

doi = "10.1177/2040620715596715",

language = "English (US)",

volume = "6",

pages = "253--261",

journal = "Therapeutic Advances in Hematology",

issn = "2040-6207",

publisher = "Sage Publications",

number = "5",

}

TY - JOUR

T1 - The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia

AU - Yilmaz, Musa

AU - Richard, Samantha

AU - Jabbour, Elias

PY - 2015/10

Y1 - 2015/10

N2 - Antibody-drug conjugates (ADCs) are likely to make a significant contribution in the treatment of acute lymphoblastic leukemia (ALL) by combining the cytotoxicity of chemotherapy with the specificity of monoclonal antibodies. CD22, an endocytic receptor expressed by the majority of B cells, is an excellent target for ADCs. Inotuzumab ozogamicin (INO) is an ADC that consists of a cytotoxic moiety (derivative of calicheamicin) attached to a humanized monoclonal anti-CD22 antibody. As a single agent, INO, was shown to be effective with an objective response rate of 50% in the treatment of relapsed and refractory CD22 positive ALL patients. Clinical trials investigating the combination of INO with the conventional chemotherapies are ongoing. This review summarizes the clinical potential of INO in treatment of relapsed and refractory ALL, based on currently available data in the literature.

AB - Antibody-drug conjugates (ADCs) are likely to make a significant contribution in the treatment of acute lymphoblastic leukemia (ALL) by combining the cytotoxicity of chemotherapy with the specificity of monoclonal antibodies. CD22, an endocytic receptor expressed by the majority of B cells, is an excellent target for ADCs. Inotuzumab ozogamicin (INO) is an ADC that consists of a cytotoxic moiety (derivative of calicheamicin) attached to a humanized monoclonal anti-CD22 antibody. As a single agent, INO, was shown to be effective with an objective response rate of 50% in the treatment of relapsed and refractory CD22 positive ALL patients. Clinical trials investigating the combination of INO with the conventional chemotherapies are ongoing. This review summarizes the clinical potential of INO in treatment of relapsed and refractory ALL, based on currently available data in the literature.

KW - acute lymphoblastic leukemia

KW - inotuzumab ozogamicin

KW - refractory

KW - relapsed

KW - salvage

UR - http://www.scopus.com/inward/record.url?scp=84993790947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993790947&partnerID=8YFLogxK

U2 - 10.1177/2040620715596715

DO - 10.1177/2040620715596715

M3 - Review article

C2 - 26425338

AN - SCOPUS:84993790947

SN - 2040-6207

VL - 6

SP - 253

EP - 261

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

IS - 5

ER -

The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this